Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony F Shields

Showing results (91-100 of 186) with videos related to

Pageof 19
Sort By:
Theranostics|January 3, 2017
Preclinical Applications of 3'-Deoxy-3'-[<sup>18</sup>F]Fluorothymidine in Oncology - A Systematic ReviewSonja Schelhaas, Kathrin Heinzmann, Vikram R Bollineni, et al.
Oncoimmunology|September 17, 2020
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patientsLawrence G Lum, Archana Thakur, Minsig Choi, et al.
The Oncologist|June 6, 2018
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric AdenocarcinomaMohamed E Salem, Alberto Puccini, Joanne Xiu, et al.
Palliative Medicine Reports|December 8, 2022
Preferences and Attitudes of Cardiologists in Management of Patients with CancerIbrahim Azar, Stephani Wang, Vikram Dhillon, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancerBassel F El-Rayes, Mark M Zalupski, Stephanie G Manza, et al.
Clinical Colorectal Cancer|August 16, 2005
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group studyCynthia G Leichman, Jacqueline K Benedetti, Mark M Zalupski, et al.
Current Colorectal Cancer Reports|September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current StatusThierry André, Timothy Iveson, Roberto Labianca, et al.
British Journal of Cancer|May 13, 2023
Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)Seohyuk Lee, Chao Ma, Qian Shi, et al.
Oncotarget|November 22, 2017
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancersMohamed E Salem, Benjamin A Weinberg, Joanne Xiu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Using Radiolabeled 3'-Deoxy-3'-<sup>18</sup>F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung CancerChristopher I McHugh, Monica R Thipparthi, Jawana M Lawhorn-Crews, et al.
Pageof 19

Showing results (91-100 of 186) with videos related to

Sort By:
Pageof 19
Theranostics|January 3, 2017
Preclinical Applications of 3'-Deoxy-3'-[<sup>18</sup>F]Fluorothymidine in Oncology - A Systematic ReviewSonja Schelhaas, Kathrin Heinzmann, Vikram R Bollineni, et al.
Oncoimmunology|September 17, 2020
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patientsLawrence G Lum, Archana Thakur, Minsig Choi, et al.
The Oncologist|June 6, 2018
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric AdenocarcinomaMohamed E Salem, Alberto Puccini, Joanne Xiu, et al.
Palliative Medicine Reports|December 8, 2022
Preferences and Attitudes of Cardiologists in Management of Patients with CancerIbrahim Azar, Stephani Wang, Vikram Dhillon, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancerBassel F El-Rayes, Mark M Zalupski, Stephanie G Manza, et al.
Clinical Colorectal Cancer|August 16, 2005
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group studyCynthia G Leichman, Jacqueline K Benedetti, Mark M Zalupski, et al.
Current Colorectal Cancer Reports|September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current StatusThierry André, Timothy Iveson, Roberto Labianca, et al.
British Journal of Cancer|May 13, 2023
Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)Seohyuk Lee, Chao Ma, Qian Shi, et al.
Oncotarget|November 22, 2017
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancersMohamed E Salem, Benjamin A Weinberg, Joanne Xiu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Using Radiolabeled 3'-Deoxy-3'-<sup>18</sup>F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung CancerChristopher I McHugh, Monica R Thipparthi, Jawana M Lawhorn-Crews, et al.
Pageof 19